Mind Medicine (MindMed) Inc. announced that it has completed enrollment and dosing in Study MMED008, the Company's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD. Study MMED008 is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study. The trial has enrolled 198 participants who were randomized to receive a single administration of 25 ug, 50 ug, 100 ug or 200 ug of MM-120, or placebo.

The primary objective of the study is to determine the dose-response relationship of four doses of MM-120 versus placebo as measured by the change in Hamilton Anxiety Rating Scale (HAM-A) from baseline to week 4. Key secondary objectives, measured up to 12 weeks after the single administration, include assessments of anxiety symptoms, safety and tolerability, as well as other measures of efficacy and quality of life.